These findings highlight the EGR1–ATF3 signaling axis as a critical driver of MuSC death and inflammaging in PMD, and suggest that its targeted inhibition may offer a promising therapeutic strategy for preventing or treating PMD. The gene discussed is ATF3; the disease is Pelizeaus-Merzbacher spectrum disorder.